DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
The generic ingredient in VIMPAT is lacosamide. There are twenty-two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the lacosamide profile page.
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 022254
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 022254
|Physiological Effect||Decreased Central Nervous System Disorganized Electrical Activity |
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||SOLUTION;INTRAVENOUS||Strength||200MG/20ML (10MG/ML)|
|Approval Date:||Oct 28, 2008||TE:||RLD:||Yes|
|Patent:||Get Started for $10||Patent Expiration:||Mar 17, 2022||Product Flag?||Y||Substance Flag?||Y||Delist Request?|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Patent No.||Patent Expiration|
|Ucb Inc||VIMPAT||lacosamide||SOLUTION;INTRAVENOUS||022254-001||Oct 28, 2008||Get Started for $10||Get Started for $10|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>Patent No.||>Patent Expiration|
Complete Access Available with Subscription